Humanigen Inc
NASDAQ:HGEN
Intrinsic Value
Humanigen, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
HGEN
stock under the Base Case scenario is
0.1076
USD.
Compared to the current market price of 0.0001 USD,
Humanigen Inc
is
Undervalued by 100%.
Humanigen Inc's market capitalization is 23.8k USD.
HGEN stock price is 0.0001 USD.
HGEN stock price (0.0001 USD) is 100% less than its Intrinsic Value (0.1076 USD).
HGEN. Open DCF Valuation
HGEN stock price (0.0001 USD) is 100% less than its Relative Value (0.1076 USD). Open Relative Valuation
HGEN.
HGEN's Revenue has dropped by 59% over the past 12 months.
HGEN's ROE (Return on Equity) has significantly increased in the last 3 years from -43 611% to 144%.
HGEN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 699% to 127%.
HGEN has negative Operating Income for the last twelve months.
HGEN has negative Net Income for the last twelve months.
HGEN's ROE (Return on Equity) for the past 12 months is very high and is equal to 144%.
HGEN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 127%.
HGEN has negative Free Cash Flow for the last twelve months.
HGEN has negative three-year average ROE (Return on Equity): -2 913%. The company is not efficient at transforming stockholders' equity into net income.
HGEN has very high three-year average ROIC (Return on Invested Capital): 642%. The company is very efficient at using invested capital to generate operating income.
HGEN's short-term liabilties (53m USD) exceed its short-term assets (5m USD).
HGEN's long-term liabilties (55m USD) exceed its long-term assets (5m USD).
HGEN's D/E (Debt to Equity) is very low and is equal to 0.
HGEN's Altman Z-Score is very low and is equal to -233.36.
HGEN doesn't generate enough operating income (-52m USD) to safely cover interest payments on its debt (770k USD).
Fundamental Analysis
Humanigen Inc
Balance Sheet Decomposition
Humanigen Inc
| Current Assets | 5m |
| Cash & Short-Term Investments | 3.1m |
| Other Current Assets | 1.9m |
| Non-Current Assets | 100k |
| Other Non-Current Assets | 100k |
| Current Liabilities | 53.3m |
| Accounts Payable | 38.4m |
| Accrued Liabilities | 14m |
| Other Current Liabilities | 900k |
| Non-Current Liabilities | 1.5m |
| Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Humanigen Inc
|
Revenue
|
1.7m
USD
|
|
Operating Expenses
|
-53.7m
USD
|
|
Operating Income
|
-52m
USD
|
|
Other Expenses
|
-1.6m
USD
|
|
Net Income
|
-53.6m
USD
|
Free Cash Flow Analysis
Humanigen Inc
What is Free Cash Flow?
HGEN Profitability Score
Profitability Due Diligence
Humanigen Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Humanigen Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
HGEN Solvency Score
Solvency Due Diligence
Humanigen Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Score
Humanigen Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HGEN Price Targets Summary
Humanigen Inc
Ownership
HGEN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
HGEN Price
Humanigen Inc
| Average Annual Return | 75.43% |
| Standard Deviation of Annual Returns | 308.39% |
| Max Drawdown | -100% |
| Market Capitalization | 23.8k USD |
| Shares Outstanding | 238 160 000 |
| Percentage of Shares Shorted | 3.88% |
Company Profile
Humanigen Inc
Country
Industry
Market Cap
Dividend Yield
Description
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily with acute and chronic conditions. The Company’s lead product candidate, lenzilumab, and its other two product candidates, ifabotuzumab (iFab) and HGEN005, are Humaneered monoclonal antibodies. Its lenzilumab product is a monoclonal antibody that has been demonstrated to neutralize human granulocyte-macrophage colony-stimulating factor (GM-CSF). Its ifabotuzumab product is focused on the EphA3 receptor. Its HGEN005 product is selectively targeting the eosinophil receptor EMR1. Its subsidiaries include Humanigen, Ltd., Humanigen Australia Pty, Ltd. and Humanigen Europe, Ltd.
You don't have any saved screeners yet
